Dr. Valeria Bottici

Valeria Bottici was born in Livorno on 8 February 1969.

Education

1997

Degree in Medicine and Surgery, University of Pisa

2003

Specialisation in Endocrinology and Metabolic Diseases, University of Pisa

2008

PhD in Endocrine and Metabolic Sciences, University of Pisa

Clinical activity

Since May 2019 she has been a permanent Consultant Physician at the Endocrinology Unit 1 of Pisa University Hospital. She currently works as a Consultant Physician at the Endocrinology Unit 2 of Cisanello Hospital and carries out research in thyroid oncology.

Research

Since 1997 she has carried out research in thyroid oncology, with a particular interest in:

• diagnosis and treatment of thyroid tumours
• pathogenesis and treatment of multiple endocrine neoplasia
• use of recombinant human TSH in the diagnosis and treatment of thyroid tumours
• molecular analysis of pathogenic molecular events in thyroid tumours (papillary, follicular, anaplastic and medullary)

Awards and grants

• Winner of an annual FIRC research grant in 2004, 2005 and 2006
• Winner of a research fellowship at the Department of Endocrinology and Metabolism, Orthopaedics and Traumatology, Occupational Medicine for the academic years 2005–2009 and 2013–2019

Scientific societies

• Italian Society of Endocrinology (SIE)
• Association of Former Students of Pisa Endocrinology (AAEP)
• Italian Thyroid Association (AIT)
• European Thyroid Association (ETA)
• Association of Medical Endocrinologists (AME)

Clinical trials with investigational drugs

Sub-Investigator in the following studies:

• «Open-label phase II study to evaluate the efficacy and tolerability of ZD6474 (Zactima™) 100 mg monotherapy in patients with locally advanced or metastatic hereditary medullary thyroid cancer» (D4200C00068)
• «International, randomised, double-blind, placebo-controlled, multicentre phase II study to evaluate the efficacy of ZD6474 (ZACTIMA™) versus placebo in patients with locally advanced unresectable or metastatic medullary thyroid carcinoma» (D4200C00058)
• «A phase 3 trial of XL184 randomized, placebo-controlled, double-blinded study of XL184 (Exelixis) as single-agent therapy in 315 patients with unresectable, locally advanced or metastatic medullary thyroid cancer»
• «XL184-401: A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients»
• «A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer Experience Grade 2 or Higher Adverse Events during the First 12 Months of Treatment with Vandetanib» (D4200C00088)
• «An International, Randomised, Double-Blind, Two-Arm Study to Evaluate the Safety and Efficacy of Vandetanib 150 and 300 mg/day in Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma with Progressive or Symptomatic Disease» (D4200C00097)
• «A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer» (D1532C00065)

Publications

Author of 60 publications in international and national journals and of more than 200 presentations of original work at national and international conferences.

Publications on PubMed